255 related articles for article (PubMed ID: 25545782)
1. Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of β-eudesmol in human cholangiocarcinoma xenografted nude mouse model.
Plengsuriyakarn T; Karbwang J; Na-Bangchang K
Clin Exp Pharmacol Physiol; 2015 Mar; 42(3):293-304. PubMed ID: 25545782
[TBL] [Abstract][Full Text] [Related]
2. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Activity of Atractylodes lancea (Thunb.) DC in a Hamster Model and Application of PET-CT for Early Detection and Monitoring Progression of Cholangiocarcinoma.
Plengsuriyakarn T; Matsuda N; Karbwang J; Viyanant V; Hirayama K; Na-Bangchang K
Asian Pac J Cancer Prev; 2015; 16(15):6279-84. PubMed ID: 26434829
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activities and effects of atractylodin and β-eudesmol on the cell cycle arrest and apoptosis on cholangiocarcinoma cell line.
Kotawong K; Chaijaroenkul W; Muhamad P; Na-Bangchang K
J Pharmacol Sci; 2018 Feb; 136(2):51-56. PubMed ID: 29525035
[TBL] [Abstract][Full Text] [Related]
5. Anticholangiocarcinoma activity and toxicity of the Kaempferia galanga Linn. Rhizome ethanolic extract.
Amuamuta A; Plengsuriyakarn T; Na-Bangchang K
BMC Complement Altern Med; 2017 Apr; 17(1):213. PubMed ID: 28403856
[TBL] [Abstract][Full Text] [Related]
6. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis.
Hu JH; Tang JH; Lin CH; Chu YY; Liu NJ
J Investig Med; 2018 Jan; 66(1):52-61. PubMed ID: 28912249
[TBL] [Abstract][Full Text] [Related]
7. Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET.
Sangfelt P; Sundin A; Wanders A; Rasmussen I; Karlson BM; Bergquist A; Rorsman F
J Hepatol; 2014 Dec; 61(6):1352-7. PubMed ID: 25111173
[TBL] [Abstract][Full Text] [Related]
8. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis.
Annunziata S; Caldarella C; Pizzuto DA; Galiandro F; Sadeghi R; Giovanella L; Treglia G
Biomed Res Int; 2014; 2014():247693. PubMed ID: 24955351
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models.
Plengsuriyakarn T; Viyanant V; Eursitthichai V; Picha P; Kupradinun P; Itharat A; Na-Bangchang K
BMC Complement Altern Med; 2012 Mar; 12():23. PubMed ID: 22448640
[TBL] [Abstract][Full Text] [Related]
11. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
Kim JY; Kim MH; Lee TY; Hwang CY; Kim JS; Yun SC; Lee SS; Seo DW; Lee SK
Am J Gastroenterol; 2008 May; 103(5):1145-51. PubMed ID: 18177454
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DC.
Plengsuriyakarn T; Kotawong K; Karbwang J; Na-Bangchang K
BMC Complement Med Ther; 2023 Jun; 23(1):186. PubMed ID: 37287012
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
[TBL] [Abstract][Full Text] [Related]
14. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma.
Moon CM; Bang S; Chung JB
Surg Oncol; 2011 Mar; 20(1):e10-7. PubMed ID: 19804967
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibitory effect of β-eudesmol on cholangiocarcinoma cells and its potential suppressive effect on heme oxygenase-1 production, STAT1/3 activation, and NF-κB downregulation.
Mathema VB; Chaijaroenkul W; Karbwang J; Na-Bangchang K
Clin Exp Pharmacol Physiol; 2017 Nov; 44(11):1145-1154. PubMed ID: 28732110
[TBL] [Abstract][Full Text] [Related]
16. The anticancer effects of Resina Draconis extract on cholangiocarcinoma.
Wen F; Zhao X; Zhao Y; Lu Z; Guo Q
Tumour Biol; 2016 Nov; 37(11):15203-15210. PubMed ID: 27683055
[TBL] [Abstract][Full Text] [Related]
17. Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model.
Vaeteewoottacharn K; Pairojkul C; Kariya R; Muisuk K; Imtawil K; Chamgramol Y; Bhudhisawasdi V; Khuntikeo N; Pugkhem A; Saeseow OT; Silsirivanit A; Wongkham C; Wongkham S; Okada S
Cells; 2019 May; 8(5):. PubMed ID: 31126020
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
19. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.
Petrowsky H; Wildbrett P; Husarik DB; Hany TF; Tam S; Jochum W; Clavien PA
J Hepatol; 2006 Jul; 45(1):43-50. PubMed ID: 16690156
[TBL] [Abstract][Full Text] [Related]
20. β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation.
Acharya B; Chajaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2573-2581. PubMed ID: 36037109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
